HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc. develops arenavirus-based immunotherapeutics designed to induce robust antigen-specific CD8+ T cell and antibody responses for treatment of cancer and infectious diseases. Its main product candidates include replicating and non-replicating arenaviral therapies such as HB-700 (KRAS-mutated cancers), eseba-vec/HB-200 (HPV16+ cancers), HB-300 (prostate cancer, development paused) and Gilead-partnered HB-400 (HBV) and HB-500 (HIV). The company operates through two primary segments: immuno-oncology programs and infectious disease collaborations/licensing. It advances programs via clinical trials and strategic partnerships, using contract manufacturers and global clinical sites in the U.S., Europe and other regions.
Summary from filing dated 2025-02-28
Frequently asked questions
What is HOOKIPA Pharma Inc.'s CIK number?
HOOKIPA Pharma Inc.'s SEC CIK number is 0001760542 (1760542). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find HOOKIPA Pharma Inc.'s SEC filings?
All of HOOKIPA Pharma Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.